Khomasuridze A G, Manusharova R A, Marsagishvili N G
Probl Endokrinol (Mosk). 1994 Sep-Oct;40(5):29-30.
Effects of long-acting contraceptives on mammary glands of patients with diffuse fibrocystic mastopathy were under study. A total of 206 women aged 17 to 38 were examined. In 50 of them fibrocystic mastopathy was detected by palpation, non-contrast mammography, and ultrasonic examination. On days 5-7 of the cycle the patients were injected 1 ml of depot provera or noristerate or subcutaneously implanted norplant. Injections of the two former agents were repeated in 3 months if necessary. Control examinations were carried out 3 months to 5 years after the contraceptives were started. The results indicate that long-acting contraceptives did not cause any negative changes in the course of mastopathy in 32 of 50 women. In 18 women the general status improved (pain and induration in the mammary glands disappeared), mammographic, thermographic, and ultrasonic data improved, this prompting us to continue our research.
正在研究长效避孕药对患有弥漫性纤维囊性乳腺病患者乳腺的影响。共检查了206名年龄在17至38岁之间的女性。其中50名通过触诊、无对比乳腺X线摄影和超声检查发现患有纤维囊性乳腺病。在月经周期的第5 - 7天，给患者注射1毫升长效醋酸甲羟孕酮或庚炔诺酮，或皮下植入皮下埋植剂。如有必要，前两种药物在3个月后重复注射。在开始使用避孕药3个月至5年后进行对照检查。结果表明，50名女性中有32名在乳腺病病程中长效避孕药未引起任何负面变化。18名女性的总体状况有所改善（乳腺疼痛和硬结消失），乳腺X线摄影、热成像和超声检查数据有所改善，这促使我们继续研究。
